| Revision as of 18:51, 10 September 2011 editCheMoBot (talk | contribs)Bots141,565 edits Updating {{drugbox}} (no changed fields - added verified revid - updated 'DrugBank_Ref', 'UNII_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'ChEBI_Ref') per Chem/Drugbox validation (report [[Misplaced Pages talk:WikiProject_Pharmacology|er← Previous edit |
Latest revision as of 22:59, 11 January 2025 edit undoArthurfragoso (talk | contribs)Extended confirmed users, Template editors4,591 edits dark mode fix |
| (58 intermediate revisions by 29 users not shown) |
| Line 1: |
Line 1: |
|
|
{{Short description|Stimulant designer drug}} |
|
|
{{Use dmy dates|date=January 2015}} |
|
{{Drugbox |
|
{{Drugbox |
|
|
| Verifiedfields = changed |
| ⚫ |
| verifiedrevid = 399296810 |
|
|
|
| Watchedfields = changed |
| ⚫ |
| drug_name = 2-Diphenylmethylpyrrolidine |
|
|
⚫ |
| verifiedrevid = 477213213 |
|
| IUPAC_name = (''RS'')-2-(Diphenylmethyl)pyrrolidine |
|
| IUPAC_name = 2-(Diphenylmethyl)pyrrolidine |
|
| image = 2-Diphenylmethylpyrrolidine.png |
|
|
⚫ |
| image = 2-Diphenylmethylpyrrolidine.png |
|
| imagename = 1 : 1 mixture (racemate) |
|
|
|
| image_class = skin-invert-image |
|
| width = 200px |
|
|
| width = 200 |
|
| width = 200 |
|
|
| drug_name = |
|
| InChI = 1/C17H19N/c1-3-8-14(9-4-1)17(16-12-7-13-18-16)15-10-5-2-6-11-15/h1-6,8-11,16-18H,7,12-13H2 |
|
|
|
<!--Clinical data--> |
|
| InChIKey = OXOBKZZXZVFOBB-UHFFFAOYAN |
|
|
|
| tradename = |
|
⚫ |
| pregnancy_category = |
|
⚫ |
| legal_status = |
|
|
| legal_DE = NpSG |
|
|
| legal_UK = Class B |
|
⚫ |
| routes_of_administration = |
|
|
<!--Pharmacokinetic data--> |
|
⚫ |
| bioavailability = |
|
⚫ |
| protein_bound = |
|
⚫ |
| metabolism = |
|
⚫ |
| elimination_half-life = |
|
⚫ |
| excretion = |
|
|
|
|
|
<!--Identifiers--> |
|
⚫ |
| CAS_number = 119237-64-8 |
|
|
| CAS_number_Ref = {{cascite|correct|CAS}} |
|
|
| UNII_Ref = {{fdacite|correct|FDA}} |
|
|
| UNII = UH7U0MAY6C |
|
⚫ |
| ATC_prefix = |
|
⚫ |
| ATC_suffix = |
|
⚫ |
| PubChem = 1295 |
|
⚫ |
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
|
⚫ |
| DrugBank = |
|
⚫ |
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} |
|
⚫ |
| ChemSpiderID = 1256 |
|
|
|
|
|
<!--Chemical data--> |
|
⚫ |
| C=17 | H=19 | N=1 |
|
⚫ |
| smiles = c1cc(ccc1)C(c2ccccc2)C3NCCC3 |
|
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} |
|
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} |
|
| StdInChI = 1S/C17H19N/c1-3-8-14(9-4-1)17(16-12-7-13-18-16)15-10-5-2-6-11-15/h1-6,8-11,16-18H,7,12-13H2 |
|
| StdInChI = 1S/C17H19N/c1-3-8-14(9-4-1)17(16-12-7-13-18-16)15-10-5-2-6-11-15/h1-6,8-11,16-18H,7,12-13H2 |
|
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} |
|
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} |
|
| StdInChIKey = OXOBKZZXZVFOBB-UHFFFAOYSA-N |
|
| StdInChIKey = OXOBKZZXZVFOBB-UHFFFAOYSA-N |
| ⚫ |
| CAS_number = 119237-64-8 |
|
| ⚫ |
| ATC_prefix = |
|
| ⚫ |
| ATC_suffix = |
|
| ⚫ |
| PubChem = 1295 |
|
| ⚫ |
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} |
|
| ⚫ |
| ChemSpiderID = 1256 |
|
| ⚫ |
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
|
| ⚫ |
| DrugBank = |
|
| ⚫ |
| C=17|H=19|N=1 |
|
|
| molecular_weight = 237.339 |
|
| ⚫ |
| smiles = c1cc(ccc1)C(c2ccccc2)C3NCCC3 |
|
| ⚫ |
| bioavailability = |
|
| ⚫ |
| protein_bound = |
|
| ⚫ |
| metabolism = |
|
| ⚫ |
| elimination_half-life = |
|
| ⚫ |
| excretion = |
|
| ⚫ |
| pregnancy_category= |
|
| ⚫ |
| legal_status = |
|
| ⚫ |
| routes_of_administration = |
|
|
}} |
|
}} |
|
|
|
|
|
|
'''2-Diphenylmethylpyrrolidine''' ('''Desoxy-D2PM'''), also known as '''2-benzhydrylpyrrolidine''', is a ] ]. It is the 4-dehydroxylated ] of ] (D2PM), and is also similar in structure to ] (2-DPMP), both of which act as ]s (NDRIs). Like D2PM and 2-DPMP, Desoxy-D2PM is sold as a ] and has been used in the manufacture of legal highs. It has been marketed under the names '''A3A New Generation''', '''A3A Methano''', and '''Green Powder''', and has been reported to cause hallucinations, violent behavior, dilated pupils, ], and high blood pressure.<ref>{{cite journal | vauthors = De Paoli G, Brandt SD, Pounder DJ | title = Analytical characterization and rapid determination of 2-(diphenylmethyl)pyrrolidine in blood and application to an internet product | journal = Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences | volume = 879 | issue = 31 | pages = 3771–4 | date = December 2011 | pmid = 22055832 | doi = 10.1016/j.jchromb.2011.10.014 }}</ref><ref>{{Cite web|url=http://www.droganews.it/pubdownload.php?id=2472|title=2-(Diphenylmethyl)pyrrolidine (desoxy-D2PM)|format=pdf|publisher=Dipartimento Politiche Antidroga, Rome|language=IT|access-date=10 February 2012|archive-url=https://web.archive.org/web/20130227212129/http://www.droganews.it/pubdownload.php?id=2472|archive-date=27 February 2013|url-status=dead|df=dmy-all}}</ref><ref>{{cite web|url=http://ewsd.wiv-isp.be/Other%20information%20on%20new%20psychoactive%20substances/Desoxy-D2PM/Report_UK_Dec%202010_Green%20Powder%20called%20A3A%20Methano.pdf|title=Green Powder called A3A Methano|author=DC Shanie Nayar|access-date=10 February 2012|archive-url=https://web.archive.org/web/20130227212132/http://ewsd.wiv-isp.be/Other%20information%20on%20new%20psychoactive%20substances/Desoxy-D2PM/Report_UK_Dec%202010_Green%20Powder%20called%20A3A%20Methano.pdf|archive-date=27 February 2013|url-status=dead}}</ref> Literature data suggest that it can produce the same psychotropic effects as other stimulants, but with a longer duration of action.<ref>{{cite journal | vauthors = Coppola M, Mondola R | title = Research chemicals marketed as legal highs: the case of pipradrol derivatives | journal = Toxicology Letters | volume = 212 | issue = 1 | pages = 57–60 | date = July 2012 | pmid = 22564760 | doi = 10.1016/j.toxlet.2012.04.019 }}</ref> |
| ⚫ |
'''2-Diphenylmethylpyrrolidine''' is a ] drug closely related to ] and ]. It has two ]s which are used industrially in their purified form for resolution of chiral reagents during chemical synthesis.<ref>Bertelsen S, Halland N, Bachmann S, Marigo M, Braunton A, Jørgensen KA. Organocatalytic asymmetric α-bromination of aldehydes and ketones. ''Chem. Commun.'' 2005, 4821-4823 |
|
|
|
|
|
{{doi|10.1039/b509366j}}</ref> |
|
|
⚫ |
Desoxy-D2PM has two ]s which are used industrially in their purified form as ]s during chemical synthesis.<ref>{{cite journal | vauthors = Bertelsen S, Halland N, Bachmann S, Marigo M, Braunton A, Jørgensen KA | title = Organocatalytic asymmetric alpha-bromination of aldehydes and ketones | journal = Chemical Communications | issue = 38 | pages = 4821–3 | date = October 2005 | pmid = 16193126 | doi = 10.1039/b509366j }}</ref> |
|
|
|
|
|
As of 4 November 2010, the ] ] announced a ban on the importation of 2-diphenylmethylpyrrolidine, following a recommendation from the ].<ref> {{Webarchive|url=https://web.archive.org/web/20120829050643/http://www.homeoffice.gov.uk/media-centre/news/drug-import-ban |date=29 August 2012 }}, UK Home Office</ref> It was due to become a class B drug<ref name="draft legislation">{{cite web | url = http://www.legislation.gov.uk/ukdsi/2012/9780111520857/memorandum/contents | title = The Misuse of Drugs Act 1971 (Amendment) Order 2012 | access-date = 2012-03-11 | date = 2012-01-27 | format = PDF | publisher = UK Home Office | archive-date = 1 January 2013 | archive-url = https://web.archive.org/web/20130101010927/http://www.legislation.gov.uk/ukdsi/2012/9780111520857/memorandum/contents | url-status = live }}</ref> on 28 March 2012,<ref name="ACMD's comments">{{cite web | url = http://www.homeoffice.gov.uk/publications/alcohol-drugs/drugs/2-dpmp-compounds/D2PM?view=Binary | title = Government accepts ACMD's advice to schedule D2PM, 2-DPMP and phenzepam | access-date = 2012-03-11 | date = 2012-01-27 | format = PDF | publisher = UK Home Office | archive-date = 6 April 2012 | archive-url = https://web.archive.org/web/20120406094033/http://www.homeoffice.gov.uk/publications/alcohol-drugs/drugs/2-dpmp-compounds/D2PM?view=Binary | url-status = live }}</ref> but the bill was scrapped, due to the presence of two ]s included in the bill that were later recommended to remain uncontrolled.<ref>{{cite web | url = http://www.homeoffice.gov.uk/publications/agencies-public-bodies/acmd1/acmd-steroids-advice-2012?view=Standard&pubID=1007793 | title = ACMD letter on further advice on the classification of two steroidal substances - February 2012 | access-date = 2012-03-18 | date = 2012-02-14 | format = PDF | publisher = UK Home Office | archive-date = 5 April 2012 | archive-url = https://web.archive.org/web/20120405213251/http://www.homeoffice.gov.uk/publications/agencies-public-bodies/acmd1/acmd-steroids-advice-2012?view=Standard&pubID=1007793 | url-status = live }}</ref> |
|
|
|
|
|
It was made a class B drug and placed in Schedule I on 13 June 2012.<ref name="control 2dpmp">{{cite web | url = http://homeoffice.gov.uk/about-us/corporate-publications-strategy/home-office-circulars/circulars-2012/014-2012/ | title = A Change to the Misuse of Drugs Act 1971: control of pipradrol-related compounds and phenazepam | access-date = 2012-07-30 | date = 7 Jun 2012 | publisher = UK Home Office | archive-date = 30 October 2012 | archive-url = https://web.archive.org/web/20121030144153/http://www.homeoffice.gov.uk/about-us/corporate-publications-strategy/home-office-circulars/circulars-2012/014-2012/ | url-status = live }}</ref> |
|
|
|
|
|
== References == |
|
== References == |
| Line 44: |
Line 61: |
|
{{DEFAULTSORT:Diphenylmethylpyrrolidine}} |
|
{{DEFAULTSORT:Diphenylmethylpyrrolidine}} |
|
] |
|
] |
|
|
] |
|
] |
|
] |
|
|
] |
|
|
|
|
|
|
|
{{nervous-system-drug-stub}} |
|